Zentek Ltd. (ZEN.V)
| Previous Close | 1.5100 |
| Open | 1.4700 |
| Bid | 1.4600 x 0 |
| Ask | 1.5000 x 0 |
| Day's Range | 1.4700 - 1.5400 |
| 52 Week Range | 1.3000 - 2.3000 |
| Volume | |
| Avg. Volume | 37,454 |
| Market Cap | 148.117M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Zentek Provides ZenGUARD(TM) Business Update
GUELPH, ON / ACCESSWIRE / April 25, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is pleased to provide an update on its ZenGUARD™ platform. The ...
- ACCESSWIRE
Zentek Announces U.S. Distribution Agreement for ZenGUARDTM-Enhanced Surgical Masks with Medwell Solutions
GUELPH, ON / ACCESSWIRE / April 3, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, is pleased to announce that it has entered into a definitive distribution ...
- ACCESSWIRE
Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA
GUELPH, ON / ACCESSWIRE / March 25, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera") has completed testing demonstrating that its C19HBA SARS-CoV-2 ...
